Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.36 |
| ▸ | MYLK | Q15746 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838378 | 0.86 | HTR2A (0.38) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL8319222 | 0.76 | SIGMAR1 (0.44) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL6015848 | 0.76 | SIGMAR1 (0.44) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL8448934 | 0.76 | HTR2A (0.40) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL1999141 | 0.76 | HTR2A (0.40) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL8655904 | 0.74 | PRKCE (0.51) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL8318760 | 0.74 | HTR2A (0.48) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL1991214 | 0.74 | HTR2A (0.48) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL8324461 | 0.74 | HTR2A (0.48) | HTR2AHTR2CSIGMAR1PRKCEMYLK | |
| SCHEMBL1993818 | 0.74 | HTR2A (0.45) | HTR2AHTR2CSIGMAR1PRKCEMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | HTR2A 1080/4885HTR2C 648/4885SIGMAR1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.